INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES

Much attention has been recently paid to the study of interleukin 6 (IL-6) among the cytokines involved in the development of immune inflammatory rheumatic diseases (IIRDs). The introduction of monoclonal antibodies that inhibit the activity of IL-6 (tocilizumab, TCZ) in clinical practice in 2010 is...

Full description

Bibliographic Details
Main Authors: E. L. Nasonov, A. M. Lila
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2018-01-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2461
id doaj-a6954bf283e34586bb9f3bc95205fbf7
record_format Article
spelling doaj-a6954bf283e34586bb9f3bc95205fbf72021-08-02T09:05:50ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922018-01-0155659059910.14412/1995-4484-2017-590-5992282INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPESE. L. Nasonov0A. M. Lila1V.A. Nasonova Research Institute of Rheumatology, Moscow; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, MoscowV.A. Nasonova Research Institute of Rheumatology, MoscowMuch attention has been recently paid to the study of interleukin 6 (IL-6) among the cytokines involved in the development of immune inflammatory rheumatic diseases (IIRDs). The introduction of monoclonal antibodies that inhibit the activity of IL-6 (tocilizumab, TCZ) in clinical practice in 2010 is one of the biggest advances in IIRD treatment in the early 21st century. IL-6 inhibition is now regarded as one of the most promising areas in the treatment of rheumatoid arthritis (RA), many other inflammatory diseases, and malignant neoplasms. The data obtained in international studies are confirmed by extensive Russian experience with TCZ used to treat RA in the LORNET study that has established the rapid and steady-state clinical effect of the drug, better quality of life in the patients, slower progression of joint destruction, positive changes in the ultrasound signs of articular inflammation and in the immunological biomarkers of inflammatory activity and identified the immunological and immunogenetic predictors for the efficiency of the drug. There is recent evidence that TCZ is highly effective in treating large-vessel vasculitis – giant cell arteritis concurrent with polymyalgia rheumatica and Takayasu’s arteritis. Noteworthy are the achievements by the Russian scientists (BIOCAD) who have designed BCD-089 that is a human anti-IL-6 receptor monoclonal antibody. IL-6 inhibition is one of the most rapidly developing areas of pharmacotherapy for human IIRDs. Further deciphering the mechanisms determining the physiological and pathological effects of IL-6 along with the design of novel drugs that block the effects of this cytokine is of considerable importance for the progress of rheumatology and many other branches of modern medicine.https://rsp.mediar-press.net/rsp/article/view/2461rheumatoid arthritisinterleukin 6tocilizumab
collection DOAJ
language Russian
format Article
sources DOAJ
author E. L. Nasonov
A. M. Lila
spellingShingle E. L. Nasonov
A. M. Lila
INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
Научно-практическая ревматология
rheumatoid arthritis
interleukin 6
tocilizumab
author_facet E. L. Nasonov
A. M. Lila
author_sort E. L. Nasonov
title INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
title_short INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
title_full INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
title_fullStr INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
title_full_unstemmed INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
title_sort inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2018-01-01
description Much attention has been recently paid to the study of interleukin 6 (IL-6) among the cytokines involved in the development of immune inflammatory rheumatic diseases (IIRDs). The introduction of monoclonal antibodies that inhibit the activity of IL-6 (tocilizumab, TCZ) in clinical practice in 2010 is one of the biggest advances in IIRD treatment in the early 21st century. IL-6 inhibition is now regarded as one of the most promising areas in the treatment of rheumatoid arthritis (RA), many other inflammatory diseases, and malignant neoplasms. The data obtained in international studies are confirmed by extensive Russian experience with TCZ used to treat RA in the LORNET study that has established the rapid and steady-state clinical effect of the drug, better quality of life in the patients, slower progression of joint destruction, positive changes in the ultrasound signs of articular inflammation and in the immunological biomarkers of inflammatory activity and identified the immunological and immunogenetic predictors for the efficiency of the drug. There is recent evidence that TCZ is highly effective in treating large-vessel vasculitis – giant cell arteritis concurrent with polymyalgia rheumatica and Takayasu’s arteritis. Noteworthy are the achievements by the Russian scientists (BIOCAD) who have designed BCD-089 that is a human anti-IL-6 receptor monoclonal antibody. IL-6 inhibition is one of the most rapidly developing areas of pharmacotherapy for human IIRDs. Further deciphering the mechanisms determining the physiological and pathological effects of IL-6 along with the design of novel drugs that block the effects of this cytokine is of considerable importance for the progress of rheumatology and many other branches of modern medicine.
topic rheumatoid arthritis
interleukin 6
tocilizumab
url https://rsp.mediar-press.net/rsp/article/view/2461
work_keys_str_mv AT elnasonov inhibitionofinterleukin6inimmuneinflammatoryrheumaticdiseasesachievementsprospectsandhopes
AT amlila inhibitionofinterleukin6inimmuneinflammatoryrheumaticdiseasesachievementsprospectsandhopes
_version_ 1721235663570862080